126114-09-8

Basic information

• Product Name: 1-tert-Butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate
• Synonyms: 1-tert-Butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate;1-tert-butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate(WXG01136)
• CAS NO: 126114-09-8
• Molecular Formula: C₁₃H₂₁NO₄
• Molecular Weight: 255.31014
• Mol File: 126114-09-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 331.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.109±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.54±0.40(Predicted)
• CAS DataBase Reference: 1-tert-Butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-Butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate(126114-09-8)
• EPA Substance Registry System: 1-tert-Butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate(126114-09-8)

Safety Data

• Hazardous Substances Data: 126114-09-8(Hazardous Substances Data)

Usage

General Description

1-tert-Butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate is a chemical compound with the molecular formula C16H25NO4. It is a dihydropyridine-based compound, and is commonly used as a calcium channel blocker in the treatment of hypertension and angina pectoris. It works by relaxing the blood vessels and reducing the workload of the heart, which helps to lower blood pressure and improve blood flow to the heart. 1-tert-Butyl 3-ethyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate is also used in the synthesis of pharmaceutical drugs, and has potential applications in research and the pharmaceutical industry. However, it is important to handle and use this compound with care, as it may pose potential risks to human health and the environment.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 4644-61-5 ethyl 4-piperidone-3-carboxylate hydrochloride 
• 98977-34-5 1-tert-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate 

Downstream Products

• 319911-79-0 ethyl 1-N-(t-butoxycarbonyl)-3-phenylmethyl-1,2,3,6-tetrahydropyridine-3-carboxylate 
• 86447-11-2 1-tert-butoxycarbonyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 319911-88-1 (3S,4S,5R)-3-Bromo-4-hydroxy-5-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 319911-73-4 (3S,4S,5R)-3-bromo-1-N-(t-butoxycarbonyl)-4-hydroxy-5-(pivaloyloxymethyl)piperidine 

Relevant articles and documents

FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS

The present disclosure relates to compounds of formula (Ι') and pharmaceutically acceptable salts thereof useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions thereof, and methods of use thereof. Compounds as disclo

Carbamoyl tetrahydropyridine derivatives

Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R1and R2are identical or different, and each represents a hydrogen atom, a C1-C5alkyl group, or the like; Y1-Y2represents (R4)C═C(R5), (R6)C═N, N═N, (R7)N—CO, or N═C(R8); X1, X2, and X3are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R3, R4, R5, and R6are identical or different, and each represents a hydrogen atom or an alkyl group; R7represents a hydrogen atom, a C1-C5alkyl group, or the like; and R8represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.

Synthesis of the sialidase inhibitor siastatin B.

[structure] The resolved piperidinecarboxylate (R)-7 was converted to siastatin B (1) by an efficient and stereoselective sequence that includes a bromo-beta-lactonization and an N-acyliminium azidation. Two analogues (3 and 4) of siastatin were also prepared.